Rallybio Corp

-0.50 (-9.35%)
4:06:08 PM EDT: $4.92 +0.07 (+1.44%)
Earnings Announcements

Rallybio Reports Third Quarter Results

Published: 11/07/2022 14:06 GMT
Rallybio Corp (RLYB) - Rallybio Reports Third Quarter 2022 Financial Results.
Q3 Loss per Share $0.60.
Preliminary Results From Phase 1b Study of Rlyb212 Showed Rapid and Complete Elimination of Transfused Platelets in Subjects.
Q3 Earnings per Share View $-0.54 -- Refinitiv Ibes Data (analyst estimates).
Proof-of-concept Data Expected in 1q 2023.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.59

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.59

More details on our Analysts Page.